|
|
 Previous Article | Table of Contents | Next Article 
The interleukin-2 receptor: a target for monoclonal antibody treatment of
human T-cell lymphotrophic virus I-induced adult T-cell leukemia
TA Waldmann, JD White, CK Goldman, L Top, A Grant, R Bamford, E Roessler, ID Horak, S Zaknoen and C Kasten-Sportes
Metabolism Branch and Laboratory of Pathology, National Cancer Institute,
National Institutes of Health, Bethesda, MD 20892.
Adult T-cell leukemia (ATL) is a malignancy of mature lymphocytes caused by
the retrovirus human T-cell lymphotrophic virus-I (HTLV-I). It is an
aggressive leukemia with an overall mortality rate of 50% within 5 months;
no conventional chemotherapy regimen appears successful in inducing
long-term disease-free survival in ATL patients. However, ATL cells
constitutively express high-affinity interleukin-2 receptors (IL-2Rs)
identified by the anti-Tac monoclonal antibody, whereas normal resting
cells do not. To exploit this difference in receptor expression, we
administered anti-Tac intravenously (IV) to 19 patients with ATL. In
general the patients did not suffer untoward reactions, and in 18 of 19
cases did not have a reduction in normal formed elements of the blood.
Seven patients developed remissions that were mixed (1 patient), partial (4
patients), or complete (2 patients), with partial and complete remissions
lasting from 9 weeks to more than 3 years as assessed by routine
hematologic tests, immunofluorescence analysis, and molecular genetic
analysis of T-cell receptor gene rearrangements and of HTLV-I proviral
integration. Furthermore, remission was associated with a return to normal
serum calcium levels and an improvement of liver function tests. Remission
was also associated in some cases with an amelioration of the profound
immunodeficiency state that characterizes ATL. Thus the use of a monoclonal
antibody that blocks the interaction of IL-2 with its receptor expressed on
ATL cells provides a rational approach for treatment of this aggressive
malignancy.
Volume 82,
Issue 6,
pp. 1701-1712,
09/15/1993
Copyright © 1993 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
C. A. Pise-Masison, M. Radonovich, K. Dohoney, J. C. Morris, D. O'Mahony, M.-J. Lee, J. Trepel, T. A. Waldmann, J. E. Janik, and J. N. Brady
Gene expression profiling of ATL patients: compilation of disease-related genes and evidence for TCF4 involvement in BIRC5 gene expression and cell viability
Blood,
April 23, 2009;
113(17):
4016 - 4026.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Chen, M. Zhang, W. Ju, and T. A. Waldmann
Effective treatment of a murine model of adult T-cell leukemia using depsipeptide and its combination with unmodified daclizumab directed toward CD25
Blood,
February 5, 2009;
113(6):
1287 - 1293.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G P Taylor
Molecular aspects of HTLV-I infection and adult T-cell leukaemia/lymphoma
J. Clin. Pathol.,
December 1, 2007;
60(12):
1392 - 1396.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. E. Dearden
Role of antibody therapy in lymphoid malignancies
Br. Med. Bull.,
September 1, 2007;
83(1):
275 - 290.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Binder, F.-N. Vogtle, S. Michelfelder, F. Muller, G. Illerhaus, S. Sundararajan, R. Mertelsmann, and M. Trepel
Identification of Their Epitope Reveals the Structural Basis for the Mechanism of Action of the Immunosuppressive Antibodies Basiliximab and Daclizumab
Cancer Res.,
April 15, 2007;
67(8):
3518 - 3523.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Zhang, Z. Yao, Z. Zhang, K. Garmestani, V. S. Talanov, P. S. Plascjak, S. Yu, H.-S. Kim, C. K. Goldman, C. H. Paik, et al.
The Anti-CD25 Monoclonal Antibody 7G7/B6, Armed with the {alpha}-Emitter 211At, Provides Effective Radioimmunotherapy for a Murine Model of Leukemia
Cancer Res.,
August 15, 2006;
66(16):
8227 - 8232.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Z. Zhang, M. Zhang, K. Garmestani, V. S. Talanov, P. S. Plascjak, B. Beck, C. Goldman, M. W. Brechbiel, and T. A. Waldmann
Effective treatment of a murine model of adult T-cell leukemia using 211At-7G7/B6 and its combination with unmodified anti-Tac (daclizumab) directed toward CD25
Blood,
August 1, 2006;
108(3):
1007 - 1012.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. C. Morris, J. E. Janik, J. D. White, T. A. Fleisher, M. Brown, M. Tsudo, C. K. Goldman, B. Bryant, M. Petrus, L. Top, et al.
Preclinical and phase I clinical trial of blockade of IL-15 using Mik{beta}1 monoclonal antibody in T cell large granular lymphocyte leukemia
PNAS,
January 10, 2006;
103(2):
401 - 406.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Ravandi and S. O'Brien
Chronic Lymphoid Leukemias Other Than Chronic Lymphocytic Leukemia: Diagnosis and Treatment
Mayo Clin. Proc.,
December 1, 2005;
80(12):
1660 - 1674.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S. Richardson, J. B. Budgin, J. M. Junkins-Hopkins, C. C. Vittorio, J. Lee, W. T. Miller Jr, A. H. Rook, and E. J. Kim
Low-Dose Bexarotene and Low-Dose Interferon Alfa-2b for Adult T-Cell Leukemia/Lymphoma Associated With Human T-Lymphotropic Virus 1
Arch Dermatol,
March 1, 2005;
141(3):
301 - 304.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Zhang, Z. Zhang, C. K. Goldman, J. Janik, and T. A. Waldmann
Combination therapy for adult T-cell leukemia-xenografted mice: flavopiridol and anti-CD25 monoclonal antibody
Blood,
February 1, 2005;
105(3):
1231 - 1236.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Zhang, Z. Zhang, K. Garmestani, C. K. Goldman, J. V. Ravetch, M. W. Brechbiel, J. A. Carrasquillo, and T. A. Waldmann
Activating Fc Receptors Are Required for Antitumor Efficacy of the Antibodies Directed toward CD25 in a Murine Model of Adult T-Cell Leukemia
Cancer Res.,
August 15, 2004;
64(16):
5825 - 5829.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. C. Moura, Y. Lepelletier, B. Arnulf, P. England, C. Baude, C. Beaumont, A. Bazarbachi, M. Benhamou, R. C. Monteiro, and O. Hermine
A neutralizing monoclonal antibody (mAb A24) directed against the transferrin receptor induces apoptosis of tumor T lymphocytes from ATL patients
Blood,
March 1, 2004;
103(5):
1838 - 1845.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Mandler, H. Kobayashi, E. R. Hinson, M. W. Brechbiel, and T. A. Waldmann
Herceptin-Geldanamycin Immunoconjugates: Pharmacokinetics, Biodistribution, and Enhanced Antitumor Activity
Cancer Res.,
February 15, 2004;
64(4):
1460 - 1467.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Z. Zhang, M. Zhang, C. K. Goldman, J. V. Ravetch, and T. A. Waldmann
Effective Therapy for a Murine Model of Adult T-Cell Leukemia with the Humanized Anti-CD52 Monoclonal Antibody, Campath-1H
Cancer Res.,
October 1, 2003;
63(19):
6453 - 6457.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Z. Zhang, M. Zhang, J. V. Ravetch, C. Goldman, and T. A. Waldmann
Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD2 monoclonal antibody, MEDI-507
Blood,
July 1, 2003;
102(1):
284 - 288.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. M. Foss, S. L. Aquino, and J. A. Ferry
Case 10-2003 - A 72-Year-Old Man with Rapidly Progressive Leukemia, Rash, and Multiorgan Failure
N. Engl. J. Med.,
March 27, 2003;
348(13):
1267 - 1275.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A.C. Church
Clinical advances in therapies targeting the interleukin-2 receptor
QJM,
February 1, 2003;
96(2):
91 - 102.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Zhang, Z. Yao, K. Garmestani, D. B. Axworthy, Z. Zhang, R. W. Mallett, L. J. Theodore, C. K. Goldman, M. W. Brechbiel, J. A. Carrasquillo, et al.
Pretargeting radioimmunotherapy of a murine model of adult T-cell leukemia with the alpha -emitting radionuclide, bismuth 213
Blood,
June 17, 2002;
100(1):
208 - 216.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. E. El-Sabban, R. A. Merhi, H. A. Haidar, B. Arnulf, H. Khoury, J. Basbous, J. Nijmeh, H. de The, O. Hermine, and A. Bazarbachi
Human T-cell lymphotropic virus type 1-transformed cells induce angiogenesis and establish functional gap junctions with endothelial cells
Blood,
May 1, 2002;
99(9):
3383 - 3389.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. P. Greer, M. C. Kinney, and T. P. Loughran Jr.
T Cell and NK Cell Lymphoproliferative Disorders
Hematology,
January 1, 2001;
2001(1):
259 - 281.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. E. Phillips, B. Herring, L. A. Wilson, M. S. Rickford, M. Zhang, C. K. Goldman, J. Y. Tso, and T. A. Waldmann
IL-2R{{alpha}}-Directed Monoclonal Antibodies Provide Effective Therapy in a Murine Model of Adult T-Cell Leukemia by a Mechanism other than Blockade of IL-2/IL-2R{{alpha}} Interaction
Cancer Res.,
December 1, 2000;
60(24):
6977 - 6984.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
J. C Morris and T. A Waldmann
Advances in interleukin 2 receptor targeted treatment
Ann Rheum Dis,
November 1, 2000;
59(90001):
i109 - 114.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. E. El-Sabban, R. Nasr, G. Dbaibo, O. Hermine, N. Abboushi, F. Quignon, J. C. Ameisen, F. Bex, H. de The, and A. Bazarbachi
Arsenic-interferon-alpha -triggered apoptosis in HTLV-I transformed cells is associated with Tax down-regulation and reversal of NF-kappa B activation
Blood,
October 15, 2000;
96(8):
2849 - 2855.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Mandler, C. Wu, E. A. Sausville, A. J. Roettinger, D. J. Newman, D. K. Ho, C. R. King, D. Yang, M. E. Lippman, N. F. Landolfi, et al.
Immunoconjugates of Geldanamycin and Anti-HER2 Monoclonal Antibodies: Antiproliferative Activity on Human Breast Carcinoma Cell Lines
J Natl Cancer Inst,
October 4, 2000;
92(19):
1573 - 1581.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. A. Waldmann, R. Levy, and B. S. Coller
Emerging Therapies: Spectrum of Applications of Monoclonal Antibody Therapy
Hematology,
January 1, 2000;
2000(1):
394 - 408.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Lau, S. Nightingale, G. P. Taylor, T. W. Gant, and A. J. Cann
Enhanced MDR1 Gene Expression in Human T-Cell Leukemia Virus-I-Infected Patients Offers New Prospects for Therapy
Blood,
April 1, 1998;
91(7):
2467 - 2474.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. P. Junghans, J. A. Carrasquillo, and T. A. Waldmann
Impact of antigenemia on the bioactivity of infused anti-Tac antibody: Implications for dose selection in antibody immunotherapies
PNAS,
February 17, 1998;
95(4):
1752 - 1757.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. K.-H. Meyer, P. Reichenbach, U. Schindler, E. Soldaini, and M. Nabholz
Interaction of STAT5 Dimers on Two Low Affinity Binding Sites Mediates Interleukin 2 (IL-2) Stimulation of IL-2 Receptor alpha Gene Transcription
J. Biol. Chem.,
December 12, 1997;
272(50):
31821 - 31828.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. D. Jennings and K. A. Foon
Recent Advances in Flow Cytometry: Application to the Diagnosis of Hematologic Malignancy
Blood,
October 15, 1997;
90(8):
2863 - 2892.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. P. Junghans, A. L. Stone, and M. S. Lewis
Biophysical Characterization of a Recombinant Soluble Interleukin 2 Receptor (Tac)
J. Biol. Chem.,
May 3, 1996;
271(18):
10453 - 10460.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Hermine, D. Bouscary, A. Gessain, P. Turlure, V. Leblond, N. Franck, A. Buzyn-Veil, B. Rio, E. Macintyre, F. Dreyfus, et al.
Treatment of Adult T-Cell Leukemia-Lymphoma with Zidovudine and Interferon Alfa
N. Engl. J. Med.,
June 29, 1995;
332(26):
1749 - 1751.
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. A. Waldmann
Human T-Cell Lymphotropic Virus Type I--Associated Adult T-Cell Leukemia: The Joseph Goldberger Clinical Investigator Lecture
JAMA,
March 1, 1995;
273(9):
735 - 737.
[Abstract]
[PDF]
|
|
|
|
|
